Eli Lilly and Company (LLY) - Stock Report

The latest reported quarter is Q1 2026, not the December 2025 quarter. Revenue rose 56% to $19.8 billion, with 65% volume growth partly offset by a 13% lower-realized-price drag; reported diluted EPS rose 170% to $8.26 and adjusted diluted EPS rose 156% to $8.55, including acquired IPR&D charges of $584 million, or about $0.52 per diluted share on the adjusted-EPS reconciliation. Mounjaro reached $8.7 billion of quarterly revenue and Zepbound reached $4.2 billion, so the value bridge is now explicitly a $12.9 billion quarterly incretin bridge. The Q1 2026 release raised 2026 guidance to $82 billion to $85 billion of revenue and $35.50 to $37.00 of adjusted EPS, up from the prior $80 billion to $83 billion and $33.50 to $35.00 base. Cash proof was strong but not unconstrained: single-quarter operating cash flow of $5.3 billion less $2.3 billion of capex left about $3.0 billion of post-capex cash, while dividends plus buybacks were about $3.9 billion.

The key macro issue is not obesity-drug demand in isolation, but whether lower realized incretin prices remain absorbable: if prescription volume keeps outrunning rebates, reimbursement pressure and capacity cost, Lilly can turn Mounjaro and Zepbound into durable post-capex cash; if access expands mainly through price concessions, the same growth can pressure gross margin, coverage and the valuation bridge.

The business operates as one pharmaceutical segment, but the economics are not evenly spread: the cardiometabolic franchise, led by tirzepatide brands Mounjaro and Zepbound, carries the current value bridge; oncology, immunology and neuroscience provide replacement depth and optionality rather than the main valuation engine.

Lilly's commercial model combines patent-protected medicines, payer access, specialist and primary-care promotion, global wholesaler distribution and a manufacturing network that must scale active ingredient, fill-finish and device capacity. The U.S. distribution channel is concentrated in major wholesalers, while LillyDirect and employer-connect initiatives are attempts to improve patient access and retain more control over the obesity-care pathway. Manufacturing is a strategic asset, not back-office infrastructure: for incretins, supply availability directly shapes revenue, market share and payer negotiations.

Management is prioritizing three valuation-relevant tasks. First, it is expanding injectable and oral incretin capacity fast enough to convert demand into durable prescriptions. Second, it is broadening the platform through orforglipron, retatrutide and other incretin assets so that the franchise does not depend on a single formulation or dosing channel. Third, it is funding external pipeline depth through business-development deals while still paying dividends and repurchasing shares, which raises the capital-allocation hurdle at the current share price.